INCOG BioPharma Invests in Second Manufacturing Building on Indiana Campus
The construction of 100,000 square-foot facility will boost the site's filling capacity to 140 million units per year.
INCOG BioPharma Services, a contract development and manufacturing organization (CDMO) whose focus is on sterile injectable biopharmaceuticals, is furthering its manufacturing services with the construction of a second 100,000 square-foot building on its campus in Fishers, IN.1
The project—scheduled to break ground in August—is expected to enhance the CDMO’s commercial-scale device assembly capacity consisting of autoinjectors, pens, syringe accessorizing, and wearable injectors.
Essentially, the new facility will boost the company’s ability to provide comprehensive, end-to-end solutions—starting with the filling process, to device assembly and final packaging, which enhances the manufacturing process. The latest facility signifies a new filling line, increasing the site's total filling capacity to 140 million units annually. While automated visual inspection and autoinjector assembly capabilities are now available, the rise in syringe filling capacity will be reflected by Q2 2025.
"We are excited about this new investment and the opportunities it brings," commented Cory Lewis, founder and CEO of INCOG. "Our customers will have access to a suite of solutions from filling through final packaging. This supply chain integration is essential in accelerating a drug product to commercial launch, and even more important in today's constrained markets as the need for sterile injectable products is quickly growing to address challenging diseases and improve healthcare outcomes. The hard work and expertise of the team we have built at INCOG has allowed us to accelerate investments and address the immediate needs of the global biopharma industry."
The construction of the new building is anticipated to create over 100 biopharma manufacturing jobs for the city of Fishers; it holds additional wait because according the Indiana Economic Development Corporation, Indiana is considered the largest exporter of pharma products in the continental United States.
"We are incredibly proud to witness INCOG's growth and expansion into a second building," said Fishers Mayor Scott Fadness. "This expansion reinforces Fishers as a leading hub for life sciences and biopharma manufacturing. INCOG has played a significant role in building the industry cluster in Fishers, and we look forward to celebrating their future successes."
The updated 140 million yearly units is attributed to the February addition of a high-speed OPTIMA filling line.2 And back in In March 2023, INCOG secured an additional $75 million of funding to go toward those efforts.
“From the beginning, we have had a big vision for what impact INCOG could make in the CDMO space,” added Lewis. “We’ve assembled a team with the experience and skill set to bring high-value sterile injectable drugs to the market with quality and speed. Seeing our capabilities and capacity expand when our partners need it most is exciting. We’re looking forward to the new partnerships and programs we plan to support in the coming year and beyond.”
References
1. INCOG BioPharma Accelerates Expansion Plans. PR Newswire. July 15, 2024. Accessed July 15, 2024. https://www.prnewswire.com/news-releases/incog-biopharma-accelerates-expansion-plans-302196830.html
2. INCOG BioPharma Services adds 100 million units of syringe/cartridge capacity. INCOG BioPharma Services. February 14, 2024. Accessed July 15, 2024. https://www.incogbiopharma.com/resources/2024/02/incog-biopharma-services-adds-100-million-units-of-syringe-cartridge-capacity/
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
